- |||||||||| Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Clinical, Journal: Acute effect of inhaled iloprost on exercise dynamic hyperinflation in COPD patients: A randomized crossover study. (Pubmed Central) - Dec 18, 2021
Despite treatment, mortality was high, and additional pediatric studies are needed for a better understanding of underlying pathologies and evidence of treatment effects. A single dose of inhaled iloprost was safe and reduced alveolar dead space fraction; however, it was not efficacious in modulating DH or improving exercise capacity in COPD patients who were not selected for the presence of PH.
- |||||||||| Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Journal: PTGER3 and MMP-2 play potential roles in diabetic nephropathy via competing endogenous RNA mechanisms. (Pubmed Central) - Dec 16, 2021
A single dose of inhaled iloprost was safe and reduced alveolar dead space fraction; however, it was not efficacious in modulating DH or improving exercise capacity in COPD patients who were not selected for the presence of PH. We speculated that the RP11-363E7.4/TTN-AS1/HOTAIRM1-hsa-miR-106b-5p-PTGER3 and LINC00960-hsa-miR-1237-3p-MMP-2 networks were associated with diabetic renal injury.
- |||||||||| Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Journal: Hyperbaric Oxygen Therapy with Iloprost Improves Digit Salvage in Severe Frostbite Compared to Iloprost Alone. (Pubmed Central) - Dec 6, 2021
This study demonstrates that the combination of HBO and iloprost was associated with higher benefit in patients with severe frostbite. The number of preserved segments was two-fold higher in the prospective cohort compared to the historical group (mean of 13 preserved segments vs. 6), and the reduction of amputation was greater in patients treated by HBO + iloprost compared with the iloprost only.
- |||||||||| Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Trial completion, Trial completion date: ThIlo: Iloprost in Acute Respiratory Distress Syndrome (clinicaltrials.gov) - Dec 3, 2021
P3, N=150, Completed,
The number of preserved segments was two-fold higher in the prospective cohort compared to the historical group (mean of 13 preserved segments vs. 6), and the reduction of amputation was greater in patients treated by HBO + iloprost compared with the iloprost only. Recruiting --> Completed | Trial completion date: Jan 2022 --> Aug 2021
- |||||||||| Ventavis (iloprost) / Bayer, J&J, University of Copenhagen, Tracleer (bosentan) / J&J, Roche
Clinical, Journal: Bosentan combined with sildenafil in the treatment of COPD patients with pulmonary arterial hypertension. (Pubmed Central) - Nov 22, 2021
Neutrophil-to-lymphocyte ratio and platelet-to-lymphocytes ratio are markers of inflammation that are reduced in patients improving with medical treatment suggesting a decreased state of inflammation before treatment in responding patients. Bosentan combined with sildenafil can reduce pulmonary artery pressure and promote the recovery of cardiopulmonary function in COPD patients with PAH.
- |||||||||| Clinical: You mean the physicians who prescribed Vioxx, Oxycontin, Risperdal, Paxil, Depakotem, Zyprexa, Aranesp, Seroquel, racleer, Ventavis, Veletri, Opsumit..please, doctors are no more ethical than the rest of the population....maybe less so. (Twitter) - Nov 21, 2021
- |||||||||| Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Clinical, Journal: Analysis of the Efficacy of Iloprost Treatment in Amputations Due to Burn. (Pubmed Central) - Nov 21, 2021
The individual and social impacts of amputations caused by burns are unquestionable. We are of the opinion that iloprost treatment is effective in reducing amputations due to burns.
- |||||||||| Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Review, Journal: Intravenous prostacyclin-analogue therapy in pulmonary arterial hypertension - A review of the past, present and future. (Pubmed Central) - Oct 31, 2021
Intravenous prostacyclin analogues are still under-used, despite available data suggesting that early and broad application of these therapies as part of risk-oriented, guideline-directed combination therapy for patients with PAH may lead to a survival benefit. This review provides a detailed overview of the drugs, infusion systems and dosing strategies used for intravenous therapy in patients with PAH.
- |||||||||| Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Clinical, Observational data, Journal: Digital Tracking of Physical Activity, Heart Rate, and Inhalation Behavior in Patients With Pulmonary Arterial Hypertension Treated With Inhaled Iloprost: Observational Study (VENTASTEP). (Pubmed Central) - Oct 30, 2021
P=N/A
This review provides a detailed overview of the drugs, infusion systems and dosing strategies used for intravenous therapy in patients with PAH. Our results suggest that despite challenges, parallel monitoring of physical activity, heart rate, and iloprost inhalation is feasible in patients with pulmonary arterial hypertension and may complement traditional measures in guiding treatment; however, the sample size of this study limits generalizability.
- |||||||||| Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
[VIRTUAL] ADENOSINE DIPHOSPHATE-INDUCED PLATELET AGGREGATION IS ENHANCED IN PLATELET-RICH PLASMA OBTAINED FROM PATIENTS WITH PRIMARY ANTIPHOSPHOLIPID SYNDROME WITH THROMBOSIS () - Oct 27, 2021 - Abstract #HEMO2021HEMO_51;
Results ADP-induced platelet aggregation were significantly higher in t-PAPS group than in controls (3 μM ADP: 69.3% ±23.8% vs 57.8% ± 24.3%, p = 0.02). No difference in AA- (52% ± 33.2% vs 56% ± 29.1%, P = 0.95) or collagen- (72% ± 19.3% vs 72.4% ± 17.3%, p = 0.51) -induced aggregation was seen between groups. The amplitude of platelet inhibition induced by SNP 3 µM (46.4% ±25.8% vs 34.7% ± 20.9%, p = 0.02) and 10 µM (31.4% ± 23.1% vs 18.8% ±14.9%, p = 0.008) or ILO 3 nM (23.3% ± 23.3% vs 12.1% ± 14%, p = 0.02) were less prominent in platelets from t-PAPS than in control volunteers. The intraplatelet levels of cAMP (6.3 ± 5.1 pmol/108 platelets vs 14.6 ± 8.1 pmol/108 platelets, p = 0.01) and cGMP (2.3 ± 1.7 pmol/108 platelets vs 4.6 ± 1.9 pmol/108 platelets, p = 0.01) was significant reduced in platelets from t-PAPS than in healthy volunteers. In platelets from t-PAPS patients the protein expression for the P2Y12 receptor was significantly greater than in platelets from healthy volunteers (0.81 ± 0.23 vs 0.53 ± 0.24, p = 0.01). The IgG antibodies obtained from t-PAPS patients produced greater amplitude of aggregation in ADP-stimulated platelet than in stimulated platelets with IgG antibodies obtained from healthy volunteers (66.2% ± 7.9% vs 52.2% ± 10.6%, P = 0.006). Ticagrelor practically abolished ADP-induced aggregation in both PRP from control and t-PAPS patients (12.9% ±6.7% vs 10.2% ± 6.4%, p = 0.09) and in WP treated with IgG antibodies (0.3% ±0.6% vs 0.0% ±0.0%, p = 0.4).Discussion Platelet activity from t-PAPS patients was enhanced upon ADP stimulation, but not by collagen or AA, mainly due to higher protein expression for P2Y12 receptor subtype and lower intraplatelet levels of cAMP and cGMP. Our findings suggest that ADP receptor antagonists can be considered as first-line therapy for treating patients with t-PAPS or in those who have contraindications to receiving aspirin.
- |||||||||| Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Clinical, Observational data, Journal: Clinical efficacy, safety, tolerability, and survival outcome of long-term inhaled iloprost treatment in the management of pulmonary arterial hypertension: Data from prospective multicenter observational OPTION study. (Pubmed Central) - Oct 22, 2021
Our findings indicate favorable efficacy, safety, and tolerability of long-term iloprost treatment in the management of PAH, whereas improved NYHA functional class was not accompanied with a significant change in 6MWD values. Patient age was a risk factor for clinical worsening, while female sex, scleroderma subtype, and lower NT-proBNP levels were associated with significantly lower mortality risk.
- |||||||||| Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
An automated network biology approach to identify novel key players involved in platelet activation and inhibition () - Oct 18, 2021 - Abstract #ECTH2021ECTH_170;
The approach was then automated using R. Ultimately, we were able to distill 30 proteins from existing phosphoproteomics datasets that putatively can be “turned on” after ADP-mediated platelet activation and subsequently switched “off” after platelet inhibition with iloprost... Our novel approach demonstrates the benefit of data integration by combining tools and datasets and visualization to obtain a more complete picture of complex molecular mechanisms such as the regulation of platelet activation and inhibition.
- |||||||||| Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Preclinical, Journal: Iloprost inhibits acute allergic nasal inflammation by GATA3 -ILC2 pathway in mice. (Pubmed Central) - Oct 7, 2021
Compared with IL 33 group, the inflammatory cell infiltration around the trachea and blood vessels of the lung tissue in the IL 33+ Iloprost group were reduced; goblet cell hyperplasia was observed in airway mucosa of IL 33 group, and the mucus secretion increased; the percentage of EOS and ILC2s in the BALF and lung single cell suspensions in IL 33+ Iloprost group were statistically lower than that of IL 33 group (p < 0.05); The mRNA expression levels of IL 5, IL 13, ST2 and GATA3 in the lung tissue of IL 33 group were higher than those in DMSO group (p < 0.05). After intervention with Iloprost, the mRNA expression levels of IL 5, IL 13, GATA3 and ST2 were lower than those in IL 33 group (p < 0.05) Iloprost may potentially inhibit the proliferation and activation of innate lymphoid cells 2 in mice with acute allergic inflammation, which maybe an effective option for the treatment of acute allergic inflammation related diseases.
- |||||||||| Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Journal: Inhaled prostacyclin analogues in COVID-19 associated acute respiratory distress syndrome: scientific rationale. (Pubmed Central) - Sep 18, 2021
P2
After intervention with Iloprost, the mRNA expression levels of IL 5, IL 13, GATA3 and ST2 were lower than those in IL 33 group (p < 0.05) Iloprost may potentially inhibit the proliferation and activation of innate lymphoid cells 2 in mice with acute allergic inflammation, which maybe an effective option for the treatment of acute allergic inflammation related diseases. Inhaled prostacyclin could be considered in patients with refractory, life-threatening hypoxia despite standard management.
- |||||||||| Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Clinical, Journal: Iloprost Attenuates Oxidative Stress-Dependent Activation of Collagen Synthesis Induced by Sera from Scleroderma Patients in Human Pulmonary Microvascular Endothelial Cells. (Pubmed Central) - Sep 8, 2021
In addition, the possibility that iloprost, a drug commonly used in SSc therapy, might modulate the above-mentioned biological phenomena has been also investigated. In this regard, as compared to sera of SSc patients, sera of iloprost-treated SSc patients failed to increased ROS levels and collagen synthesis in HPMEC, suggesting a potential antioxidant mechanism of this drug.
- |||||||||| Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Clinical, Journal: Post-infectious Digital Ischemia Successfully Treated with Iloprost in a Child. (Pubmed Central) - Sep 1, 2021
In this regard, as compared to sera of SSc patients, sera of iloprost-treated SSc patients failed to increased ROS levels and collagen synthesis in HPMEC, suggesting a potential antioxidant mechanism of this drug. No abstract available
- |||||||||| Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Journal: Long-term platelet priming after glycoprotein VI stimulation in comparison to Protease-Activating Receptor (PAR) stimulation. (Pubmed Central) - Sep 1, 2021
Furthermore, cytosolic Ca2+ measurements indicated that, when compared to PAR, prior GPVI stimulation induced a more persistent, priming activation state of platelets that influenced the response to a next agent. Overall, these data point to an unexpected priming memory of activated platelets in subacutely responding to another inhibitor or stimulus, with a higher versatility and faster offset after PAR stimulation than after GPVI stimulation.
- |||||||||| Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Journal: Tissue-Engineered Carotid Artery Interposition Grafts Demonstrate High Primary Patency and Promote Vascular Tissue Regeneration in the Ovine Model. (Pubmed Central) - Aug 29, 2021
Here we test Poly(3-hydroxybutyrate-co-3-hydroxyvalerate)Poly(ε-caprolactone) 4-mm-diameter vascular grafts equipped with vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF) and stromal cell-derived factor 1α (SDF-1α) and surface coated with heparin and iloprost (PHBV/PCL[VEGF-bFGF-SDF], n = 8) in a sheep carotid artery interposition model, using biostable vascular prostheses of expanded poly(tetrafluoroethylene) (ePTFE, n = 5) as a control...The most (4/5, 80%) of the regenerated arteries were free of calcifications but suffered from the aneurysmatic dilation. Therefore, biodegradable PHBV/PCL[VEGF-bFGF-SDF] grafts showed better short- and long-term results than bio-stable ePTFE analogues, although these scaffolds must be reinforced for the efficient prevention of aneurysms.
- |||||||||| Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
[VIRTUAL] Precision Cut Lung Slices Models for Lung Cancer Chemoprevention Investigations (ePoster Hall) - Aug 9, 2021 - Abstract #IASLCWCLC2021IASLC_WCLC_1145;
Frizzled 9 (Fzd9) is a transmembrane receptor required for the chemopreventive effects of the prostacyclin analogue iloprost in mouse models of lung carcinogenesis...Initial tests of ex vivo vinyl carbamate or NTCU treated hydrogel embedded PCLS indicate that viability can be maintained for 5-6 weeks with carcinogen exposure and that RNA can be recovered for gene expression studies. Conclusion These data present promising early-stage development of models that will improve capacity for chemoprevention drug efficacy testing prior to preclinical studies and provide opportunities for more relevant mechanistic studies.
- |||||||||| Ventavis (iloprost) / Bayer, J&J, University of Copenhagen, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Clinical, Retrospective data, Journal: Management of severe frostbite with iloprost, alteplase and heparin: a Yukon case series. (Pubmed Central) - Aug 8, 2021
Over the study period, our protocol contributed to improvement in frostbite care at our institution, resulting in a digit salvage rate comparable to other published results. Our 5-year experience shows that advanced medical care of frostbite can be achieved, even at a rural centre.
- |||||||||| Ventavis (iloprost) / Bayer, J&J, University of Copenhagen, Simdax (levosimendan IV) / AbbVie
Journal: Comparison of levosimendan, NO, and inhaled iloprost for pulmonary hypertension reversibility assessment in heart transplant candidates. (Pubmed Central) - Jul 3, 2021
Levosimendan may be a safe and effective alternative for pulmonary hypertension reversibility assessment or a valuable pre-test medical optimization tool in end-stage heart failure patient assessment for heart transplantation offering extended haemodynamic benefits. Whether it increases the rate of positive responses or allows a better selection of candidates to heart transplantation remains to be established.
- |||||||||| Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Trial completion date, Trial primary completion date: OVATION: Outpatient Vasodilator Assessment Using Iloprost in Pulmonary Hypertension (clinicaltrials.gov) - Jun 30, 2021
P4, N=50, Recruiting,
Whether it increases the rate of positive responses or allows a better selection of candidates to heart transplantation remains to be established. Trial completion date: Dec 2020 --> Dec 2022 | Trial primary completion date: Dec 2020 --> Dec 2021
- |||||||||| Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Clinical, Review, Journal: Evolution of randomized, controlled studies of medical therapy in chronic thromboembolic pulmonary hypertension. (Pubmed Central) - Jun 10, 2021
Studies of medical therapies for CTEPH have evolved since Aerosolized Iloprost Randomized (AIR), the first randomized, controlled study of a PH-targeted therapy (inhaled iloprost) to include patients with CTEPH...The 16-week Chronic Thromboembolic Pulmonary Hypertension Soluble Guanylate Cyclase-Stimulator Study 1 (CHEST-1) study was the first to operationalize these learnings, demonstrating a significant mean improvement in 6-minute walk distance (+46 m) and improvements in hemodynamic endpoints with riociguat versus placebo...Data on combinations of macitentan with phosphodiesterase type 5 inhibitors or oral prostanoids are available from MERIT, the first study to allow such regimens...Studies are also needed for multimodality treatment, including medical therapy plus BPA, and medical therapy as a bridge to PEA in selected operable patients. To address these issues and improve patient outcomes, it is vital that we learn from current studies to improve future trial design.
- |||||||||| Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
[VIRTUAL] cAMP Prevents Antibody Induced Thrombus Formation in COVID-19 (Room 2) - Jun 9, 2021 - Abstract #ISTH2021ISTH_2699;
Conclusions : Our findings indicate that COVID-19 Abs induce procoagulant PLTs and increased thrombus formation in a FcγRIIA dependent pathway. As these changes were inhibited via Iloprost, upregulation of cAMP in PLTs might be a promising future therapeutic approach for the complex coagulopathy observed in critical ill COVID-19 patients.
- |||||||||| Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Trial primary completion date: ThIlo: Iloprost in Acute Respiratory Distress Syndrome (clinicaltrials.gov) - Jun 7, 2021
P3, N=150, Recruiting,
Our findings suggest that platelets activity is increased in t-PAPS and point towards a possible role of the ADP signaling pathway in the thrombotic event seen in these patients. Trial primary completion date: Oct 2021 --> Jun 2021
|
